Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference
A live webcast and replay of the presentation will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/.
About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence and Congestive Heart Failure, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Investor Relations:Ryan Schmidtinvestors@cloverhealth.com
Press Inquiries:press@cloverhealth.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: Following the live webcast, a replay will be available on the company's website for at least 14 days. About Revolution Medicines, Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on LinkedIn. Revolution Medicines Media & Investor Contact:media@
Yahoo
a minute ago
- Yahoo
Board Declares Quarterly Dividend and Elects New Officer
WESTMINSTER, Colo., July 30, 2025 /PRNewswire/ -- Ball Corporation's (NYSE: BALL) board of directors (the "Board") today declared a cash dividend of 20 cents per share, payable September 16, 2025, to shareholders of record as of September 2, 2025. The Board also elected Edmund "Ted" Doering to serve as Chief Information Officer (CIO) of the corporation. Ted recently joined Ball to succeed Brian Gabbard, who is planning to retire from the company at the end of September. Ted brings more than three decades of global IT leadership experience, most recently serving as executive vice president and CIO at Berry Global. Before joining Berry, Ted was Chief Digital Officer at Emerson Electric and CIO of Emerson Automation Solutions. Ted has deep expertise in driving value creation, delivery execution and enterprise risk management. Conference Call Details Ball will announce its second quarter 2025 earnings on Tuesday, August 5, 2025 before trading begins on the New York Stock Exchange. At 9 a.m. Mountain Time on that day (11 a.m. Eastern Time), Ball will hold its regular quarterly conference call on the company's results and performance. Please use the following URL to join via webcast: To participate in the live call Q&A session, North American callers should use the following number, 877-497-9071. International callers should use the following number, +1 201-689-8727. For those unable to listen to the live call, a taped replay and transcript of the event will be available within 48 hours on Ball's website at under "Financial Results." About Ball Corporation Ball Corporation supplies innovative, sustainable aluminum packaging solutions for beverage, personal care and household products customers. Ball Corporation employs 16,000 people worldwide and reported 2024 net sales of $11.80 billion, which excludes the divested aerospace business. For more information, visit or connect with us on LinkedIn or Instagram. View original content to download multimedia: SOURCE Ball Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Sprouts (NASDAQ:SFM) Exceeds Q2 Expectations
Grocery store chain Sprouts Farmers Market (NASDAQ:SFM) reported Q2 CY2025 results beating Wall Street's revenue expectations , with sales up 17.3% year on year to $2.22 billion. Its GAAP profit of $1.35 per share was 9.4% above analysts' consensus estimates. Is now the time to buy Sprouts? Find out in our full research report. Sprouts (SFM) Q2 CY2025 Highlights: Revenue: $2.22 billion vs analyst estimates of $2.17 billion (17.3% year-on-year growth, 2.3% beat) EPS (GAAP): $1.35 vs analyst estimates of $1.23 (9.4% beat) Adjusted EBITDA: $217.8 million vs analyst estimates of $200.5 million (9.8% margin, 8.6% beat) EPS (GAAP) guidance for the full year is $5.26 at the midpoint, beating analyst estimates by 3.3% Operating Margin: 8.1%, up from 6.7% in the same quarter last year Free Cash Flow Margin: 2.3%, similar to the same quarter last year Same-Store Sales rose 10.2% year on year (6.7% in the same quarter last year) Market Capitalization: $15.36 billion "We are pleased with our excellent results for the second quarter," said Jack Sinclair, chief executive officer of Sprouts Farmers Market. Company Overview Playing on the secular trend of healthier living, Sprouts Farmers Market (NASDAQ:SFM) is a grocery store chain emphasizing natural and organic products. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. With $8.40 billion in revenue over the past 12 months, Sprouts is a mid-sized retailer, which sometimes brings disadvantages compared to larger competitors benefiting from better economies of scale. As you can see below, Sprouts grew its sales at a mediocre 7.5% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts), but to its credit, it opened new stores and increased sales at existing, established locations. This quarter, Sprouts reported year-on-year revenue growth of 17.3%, and its $2.22 billion of revenue exceeded Wall Street's estimates by 2.3%. Looking ahead, sell-side analysts expect revenue to grow 10.2% over the next 12 months, an acceleration versus the last six years. This projection is eye-popping and indicates its newer products will spur better top-line performance. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Store Performance Number of Stores A retailer's store count influences how much it can sell and how quickly revenue can grow. Over the last two years, Sprouts opened new stores at a rapid clip by averaging 6.4% annual growth, among the fastest in the consumer retail sector. This gives it a chance to become a large, scaled business over time. When a retailer opens new stores, it usually means it's investing for growth because demand is greater than supply, especially in areas where consumers may not have a store within reasonable driving distance. Note that Sprouts reports its store count intermittently, so some data points are missing in the chart below. Same-Store Sales A company's store base only paints one part of the picture. When demand is high, it makes sense to open more. But when demand is low, it's prudent to close some locations and use the money in other ways. Same-store sales provides a deeper understanding of this issue because it measures organic growth at brick-and-mortar shops for at least a year. Sprouts has been one of the most successful retailers over the last two years thanks to skyrocketing demand within its existing locations. On average, the company has posted exceptional year-on-year same-store sales growth of 7.5%. This performance suggests its rollout of new stores is beneficial for shareholders. We like this backdrop because it gives Sprouts multiple ways to win: revenue growth can come from new stores, e-commerce, or increased foot traffic and higher sales per customer at existing locations. In the latest quarter, Sprouts's same-store sales rose 10.2% year on year. This growth was an acceleration from its historical levels, which is always an encouraging sign. Key Takeaways from Sprouts's Q2 Results We were impressed by how significantly Sprouts blew past analysts' revenue, EPS, and EBITDA expectations this quarter. We were also glad its full-year EPS guidance exceeded Wall Street's estimates. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 2.5% to $162.01 immediately following the results. Sprouts may have had a good quarter, but does that mean you should invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
